{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T11:24:22Z","timestamp":1786965862860,"version":"build-2736575974"},"reference-count":205,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Rheumatic and autoimmune diseases have long relied on glucocorticoids and immunosuppressants for disease control, yet a true cure remains elusive; patients oscillate between remission and relapse and progressively accumulate irreversible organ damage. Chimeric antigen receptor (CAR) T cells targeting CD19 or B-cell maturation antigen (BCMA) achieve deep depletion of pathogenic B-lineage cells, enabling a subset of patients with systemic lupus erythematosus, idiopathic inflammatory myopathy, and systemic sclerosis to attain sustained remission after withdrawal of all immunosuppressants, accompanied by seroconversion of autoantibodies, normalization of complement, and reconstitution of the B-cell pool with a naive phenotype. This phenomenon suggests that, if B-cell depletion can reach the secondary lymphoid organs and inflamed tissues beyond the peripheral blood, it may \u201creset\u201d the disrupted immune homeostasis rather than merely suppress it transiently. Compared with the oncology setting, the target-cell burden in autoimmune disease is lower, cytokine release syndrome is mostly mild and self-limiting, and neurotoxicity is rare; nevertheless, prolonged B-cell aplasia, hypogammaglobulinemia, and infection risk still require disciplined management, while signals of long-term secondary malignancy await validation through longer follow-up. Next-generation engineering strategies\u2014including CD19\/BCMA dual targeting, allogeneic universal products, CAR regulatory T cells (CAR-Treg), and logic gating with safety switches\u2014are broadening indications, lowering costs, and enhancing precision and controllability. This review systematically examines the engineering principles, pharmacodynamics, cross-disease clinical evidence, distinctive safety profile, and frontier advances of CAR-T in rheumatic disease and discusses how this therapy may shift the treatment paradigm from \u201cchronic suppression\u201d toward a \u201cone-time reset\u201d, as well as the questions of durability, patient stratification, and health economics that must be answered on the path to a \u201ccure.\u201d<\/jats:p>","DOI":"10.3389\/fimmu.2026.1913968","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T10:25:52Z","timestamp":1786962352000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Chimeric antigen receptor T-cell therapy for rheumatic diseases: from B-cell depletion to immune reset and beyond"],"prefix":"10.3389","volume":"17","author":[{"given":"Yiqing","family":"Zhan","sequence":"first","affiliation":[{"name":"Department of General Medicine, the Second Affiliated Hospital of Wannan Medical College","place":["Wuhu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Gynecology, The First Affiliated Hospital of Wannan Medical College (Yijishan Hospital of Wannan Medical College)","place":["Wuhu, Anhui, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keyao","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease, Shaoyang Central Hospital","place":["Shaoyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214819","article-title":"2019 European League Against Rheumatism\/American College of Rheumatology classification criteria for systemic lupus erythematosus","volume":"78","author":"Aringer","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-216924","article-title":"2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR\/ERA-EDTA) recommendations for the management of lupus nephritis","volume":"79","author":"Fanouriakis","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1100359","article-title":"Systemic lupus erythematosus","volume":"365","author":"Tsokos","year":"2011","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-021-00668-1","article-title":"Global epidemiology of systemic lupus erythematosus","volume":"17","author":"Barber","year":"2021","journal-title":"Nat Rev Rheumatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2014.01.055","article-title":"Optimizing outcome in SLE: treating-to-target and definition of treatment goals","volume":"13","author":"Doria","year":"2014","journal-title":"Autoimmun Rev"},{"key":"B6","doi-asserted-by":"publisher","first-page":"16039","DOI":"10.1038\/nrdp.2016.39","article-title":"Systemic lupus erythematosus","volume":"2","author":"Kaul","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/nri844","article-title":"BAFF: a fundamental survival factor for B cells","volume":"2","author":"Mackay","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1172\/JCI38010","article-title":"The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus","volume":"119","author":"Cancro","year":"2009","journal-title":"J Clin Invest"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/art.30613","article-title":"A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus","volume":"63","author":"Furie","year":"2011","journal-title":"Arthritis Rheum"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/art.34400","article-title":"Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus","volume":"64","author":"Stohl","year":"2012","journal-title":"Arthritis Rheum"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2001180","article-title":"Two-year, randomized, controlled trial of belimumab in lupus nephritis","volume":"383","author":"Furie","year":"2020","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1301284","article-title":"B cell antigen presentation in the initiation of follicular helper T cell and germinal center differentiation","volume":"192","author":"Barnett","year":"2014","journal-title":"J Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2014.10.004","article-title":"T follicular helper cell differentiation, function, and roles in disease","volume":"41","author":"Crotty","year":"2014","journal-title":"Immunity"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3054","article-title":"Pathophysiology of T follicular helper cells in humans and mice","volume":"16","author":"Ueno","year":"2015","journal-title":"Nat Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2019.04.011","article-title":"T follicular helper cell biology: a decade of discovery and diseases","volume":"50","author":"Crotty","year":"2019","journal-title":"Immunity"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/art.39020","article-title":"Circulating follicular helper-like T cells in systemic lupus erythematosus: association with disease activity","volume":"67","author":"Choi","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201545760","article-title":"T follicular helper (Tfh) cells in lupus: activation and involvement in SLE pathogenesis","volume":"46","author":"Blanco","year":"2016","journal-title":"Eur J Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/nri3857","article-title":"Antibody-independent functions of B cells: a focus on cytokines","volume":"15","author":"Shen","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.10.6092","article-title":"Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis","volume":"178","author":"Duddy","year":"2007","journal-title":"J Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-02-078071","article-title":"B lymphocytes: how they develop and function","volume":"112","author":"LeBien","year":"2008","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/nri3700","article-title":"Ectopic lymphoid-like structures in infection, cancer and autoimmunity","volume":"14","author":"Pitzalis","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0060001","article-title":"Ectopic lymphoid structures support ongoing production of class-switched autoantibodies in rheumatoid synovium","volume":"6","author":"Humby","year":"2009","journal-title":"PloS Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2018.08.015","article-title":"Distinct effector B cells induced by unregulated Toll-like receptor 7 contribute to pathogenic responses in systemic lupus erythematosus","volume":"49","author":"Jenks","year":"2018","journal-title":"Immunity"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02458","article-title":"Challenges and opportunities for consistent classification of human B cell and plasma cell populations","volume":"10","author":"Sanz","year":"2019","journal-title":"Front Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3175","article-title":"Diversity, cellular origin and autoreactivity of antibody-secreting cell population expansions in acute systemic lupus erythematosus","volume":"16","author":"Tipton","year":"2015","journal-title":"Nat Immunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1038\/s41467-018-03750-7","article-title":"IL-21 drives expansion and plasma cell differentiation of autoreactive CD11c-hi T-bet+ B cells in SLE","volume":"9","author":"Wang","year":"2018","journal-title":"Nat Commun"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12741","article-title":"Extrafollicular responses in humans and SLE","volume":"288","author":"Jenks","year":"2019","journal-title":"Immunol Rev"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-020-00814-z","article-title":"Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19","volume":"21","author":"Woodruff","year":"2020","journal-title":"Nat Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.179433","article-title":"Selective CAR T cell-mediated B cell depletion suppresses IFN signature in SLE","volume":"9","author":"Wilhelm","year":"2024","journal-title":"JCI Insight"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1002795","article-title":"Type I interferon in the pathogenesis of lupus","volume":"192","author":"Crow","year":"2014","journal-title":"J Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0337679100","article-title":"Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus","volume":"100","author":"Baechler","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20021553","article-title":"Interferon and granulopoiesis signatures in systemic lupus erythematosus blood","volume":"197","author":"Bennett","year":"2003","journal-title":"J Exp Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2011.01.009","article-title":"The type I interferon system in the development of lupus","volume":"23","author":"Ronnblom","year":"2011","journal-title":"Semin Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/art.27233","article-title":"Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II\/III EXPLORER trial","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis Rheum"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/art.34359","article-title":"Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study","volume":"64","author":"Rovin","year":"2012","journal-title":"Arthritis Rheum"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-225727","article-title":"B-cell depletion in autoimmune diseases","volume":"83","author":"Schett","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1177\/0961203312471576","article-title":"B cell biology: implications for treatment of systemic lupus erythematosus","volume":"22","author":"Anolik","year":"2013","journal-title":"Lupus"},{"key":"B39","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1186\/ar3433","article-title":"Mechanisms of B cell autoimmunity in SLE","volume":"13","author":"Dorner","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220920","article-title":"B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial","volume":"81","author":"Furie","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex067","article-title":"Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples","volume":"56","author":"Reddy","year":"2017","journal-title":"Rheumatol (Oxford)"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2410965","article-title":"Efficacy and safety of obinutuzumab in active lupus nephritis","volume":"392","author":"Furie","year":"2025","journal-title":"N Engl J Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2009.184","article-title":"CD19: a promising B cell target for rheumatoid arthritis","volume":"5","author":"Tedder","year":"2009","journal-title":"Nat Rev Rheumatol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1186\/2162-3619-1-36","article-title":"CD19: a biomarker for B cell development, lymphoma diagnosis and therapy","volume":"1","author":"Wang","year":"2012","journal-title":"Exp Hematol Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01126-1","article-title":"CAR T-cell therapy in autoimmune diseases","volume":"402","author":"Schett","year":"2023","journal-title":"Lancet"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-026-04430-6","article-title":"Resetting autoimmune disease with CAR cell therapies","volume":"32","author":"Schett","year":"2026","journal-title":"Nat Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-168286","article-title":"Depletion of autoreactive immunologic memory followed by autologous hematopoietic stem cell transplantation in patients with refractory SLE induces long-term remission through de novo generation of a juvenile and tolerant immune system","volume":"113","author":"Alexander","year":"2009","journal-title":"Blood"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1519671","article-title":"CAR-T cell therapy: developments, challenges and expanded applications from cancer to autoimmunity","volume":"15","author":"Kong","year":"2025","journal-title":"Front Immunol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-12-0548","article-title":"The basic principles of chimeric antigen receptor design","volume":"3","author":"Sadelain","year":"2013","journal-title":"Cancer Discov"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.86.24.10024","article-title":"Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity","volume":"86","author":"Gross","year":"1989","journal-title":"Proc Natl Acad Sci USA"},{"key":"B55","doi-asserted-by":"publisher","first-page":"95ra73","DOI":"10.1126\/scitranslmed.3002842","article-title":"T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia","volume":"3","author":"Kalos","year":"2011","journal-title":"Sci Transl Med"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N Engl J Med"},{"key":"B57","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"N Engl J Med"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-492231","article-title":"Antibody-modified T cells: CARs take the front seat for hematologic Malignancies","volume":"123","author":"Maus","year":"2014","journal-title":"Blood"},{"key":"B59","doi-asserted-by":"publisher","first-page":"177ra38","DOI":"10.1126\/scitranslmed.3005930","article-title":"CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia","volume":"5","author":"Brentjens","year":"2013","journal-title":"Sci Transl Med"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med"},{"key":"B61","doi-asserted-by":"publisher","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci Transl Med"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.01.021","article-title":"Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells","volume":"44","author":"Kawalekar","year":"2016","journal-title":"Immunity"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1172\/JCI46110","article-title":"CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients","volume":"121","author":"Savoldo","year":"2011","journal-title":"J Clin Invest"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.09.004","article-title":"Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells","volume":"28","author":"Zhao","year":"2015","journal-title":"Cancer Cell"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3838","article-title":"4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors","volume":"21","author":"Long","year":"2015","journal-title":"Nat Med"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00023-5","article-title":"CD19-targeted CAR T cells in refractory antisynthetase syndrome","volume":"401","author":"M\u00fcller","year":"2023","journal-title":"Lancet"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aat6753","article-title":"Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function","volume":"11","author":"Salter","year":"2018","journal-title":"Sci Signal"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1038\/nature21405","article-title":"Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection","volume":"543","author":"Eyquem","year":"2017","journal-title":"Nature"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat Med"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0178-z","article-title":"Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells","volume":"558","author":"Fraietta","year":"2018","journal-title":"Nature"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1038\/ncponc0666","article-title":"Increased intensity lymphodepletion and adoptive immunotherapy - how far can we go","volume":"3","author":"Muranski","year":"2006","journal-title":"Nat Clin Pract Oncol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2004.12.003","article-title":"Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy","volume":"26","author":"Klebanoff","year":"2005","journal-title":"Trends Immunol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J Clin Invest"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-11-887067","article-title":"The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells","volume":"133","author":"Hirayama","year":"2019","journal-title":"Blood"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2011.1","article-title":"Long-lived autoreactive plasma cells drive persistent autoimmune inflammation","volume":"7","author":"Hiepe","year":"2011","journal-title":"Nat Rev Rheumatol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1038\/nri1886","article-title":"Competence and competition: the challenge of becoming a long-lived plasma cell","volume":"6","author":"Radbruch","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00721","article-title":"The maintenance of memory plasma cells","volume":"10","author":"Khodadadi","year":"2019","journal-title":"Front Immunol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02138","article-title":"Factors affecting early antibody secreting cell maturation into long-lived plasma cells","volume":"10","author":"Nguyen","year":"2019","journal-title":"Front Immunol"},{"key":"B81","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1038\/s41467-024-46226-7","article-title":"Distinct transcriptomes and autocrine cytokines underpin maturation and survival of antibody-secreting cells in systemic lupus erythematosus","volume":"15","author":"Chen","year":"2024","journal-title":"Nat Commun"},{"key":"B82","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease - a case series with follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N Engl J Med"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-02-555169","article-title":"A unique population of IgG-expressing plasma cells lacking CD19 is enriched in human bone marrow","volume":"125","author":"Mei","year":"2015","journal-title":"Blood"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2015.06.016","article-title":"Long-lived plasma cells are contained within the CD19(-)CD38(hi)CD138(+) subset in human bone marrow","volume":"43","author":"Halliley","year":"2015","journal-title":"Immunity"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2008.05.009","article-title":"Regulatory T cells and immune tolerance","volume":"133","author":"Sakaguchi","year":"2008","journal-title":"Cell"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0041-4","article-title":"Next-generation regulatory T cell therapy","volume":"18","author":"Ferreira","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/j.nantod.2026.103085","article-title":"The dual facets of B cell immunity: from pathogenic drivers to theranostic tools","volume":"69","author":"Zang","year":"2026","journal-title":"Nano Today"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1172\/JCI65689","article-title":"B cell depletion in immune thrombocytopenia reveals splenic long-lived plasma cells","volume":"123","author":"Mahevas","year":"2013","journal-title":"J Clin Invest"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206016","article-title":"The proteasome inhibitor bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus","volume":"74","author":"Alexander","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2023325","article-title":"Targeting CD38 with daratumumab in refractory systemic lupus erythematosus","volume":"383","author":"Ostendorf","year":"2020","journal-title":"N Engl J Med"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2107725","article-title":"CD19-targeted CAR T cells in refractory systemic lupus erythematosus","volume":"385","author":"Mougiakakos","year":"2021","journal-title":"N Engl J Med"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000002354","article-title":"Systematic review of chimeric antigen receptor T-cell therapy in autoimmune diseases","volume":"32","author":"Hershkowitz","year":"2026","journal-title":"J Clin Rheumatol"},{"key":"B93","doi-asserted-by":"publisher","first-page":"2956","DOI":"10.1038\/s41591-022-02091-9","article-title":"Author Correction: Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"29","author":"Mackensen","year":"2023","journal-title":"Nat Med"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2021-000538","article-title":"2021 DORIS definition of remission in SLE: final recommendations from an international task force","volume":"8","author":"van Vollenhoven","year":"2021","journal-title":"Lupus Sci Med"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2024-eular.220","article-title":"Long-term safety and efficacy of CAR T-cell therapy in patients with autoimmune disease (CASTLE study)","volume":"83","author":"Taubmann","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-019-0398-x","article-title":"The immune cell landscape in kidneys of patients with lupus nephritis","volume":"20","author":"Arazi","year":"2019","journal-title":"Nat Immunol"},{"key":"B97","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1038\/s41423-020-0472-1","article-title":"Therapeutic efficacy of anti-CD19 CAR-T cells in a mouse model of systemic lupus erythematosus","volume":"18","author":"Jin","year":"2021","journal-title":"Cellular & Molecular Immunology"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aav1648","article-title":"Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus","volume":"11","author":"Kansal","year":"2019","journal-title":"Sci Transl Med"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1007\/s12015-021-10251-6","article-title":"Treatment of systemic lupus erythematosus using BCMA-CD19 compound CAR","volume":"17","author":"Zhang","year":"2021","journal-title":"Stem Cell Rev Rep"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-225785","article-title":"BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial","volume":"83","author":"Wang","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03937-8","article-title":"Co-infusion of CD19-targeting and BCMA-targeting CAR-T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial","volume":"31","author":"Feng","year":"2025","journal-title":"Nat Med"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-04185-6","article-title":"CD19 CAR-T cells for treatment-refractory autoimmune diseases: the phase 1\/2 CASTLE basket trial","volume":"32","author":"M\u00fcller","year":"2026","journal-title":"Nat Med"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and dermatomyositis (first of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"key":"B106","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s41572-021-00321-x","article-title":"Idiopathic inflammatory myopathies","volume":"7","author":"Lundberg","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1212\/01.CON.0000511070.50715.ab","article-title":"Autoimmune myopathies","volume":"22","author":"Mammen","year":"2016","journal-title":"Continuum (Minneap Minn)"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211468","article-title":"2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"76","author":"Lundberg","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B109","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1136\/annrheumdis-2017-211400","article-title":"2016 American College of Rheumatology\/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis","volume":"76","author":"Aggarwal","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.8753","article-title":"CD19-targeting CAR T cells for myositis and interstitial lung disease associated with antisynthetase syndrome","volume":"329","author":"Pecher","year":"2023","journal-title":"JAMA"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead330","article-title":"Rescue therapy of antisynthetase syndrome with CD19-targeted CAR-T cells after failure of several B-cell depleting antibodies","volume":"63","author":"Taubmann","year":"2024","journal-title":"Rheumatol (Oxford)"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1186\/2044-5040-3-13","article-title":"Idiopathic inflammatory myopathies: pathogenic mechanisms of muscle weakness","volume":"3","author":"Rayavarapu","year":"2013","journal-title":"Skelet Muscle"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1002\/ana.20464","article-title":"Interferon-alpha\/beta-mediated innate immune mechanisms in dermatomyositis","volume":"57","author":"Greenberg","year":"2005","journal-title":"Ann Neurol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1002\/art.30513","article-title":"Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients","volume":"63","author":"Marie","year":"2011","journal-title":"Arthritis Rheum"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-223952","article-title":"Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells","volume":"82","author":"Bergmann","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204424","article-title":"2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League against Rheumatism collaborative initiative","volume":"72","author":"van den Hoogen","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"B117","doi-asserted-by":"publisher","first-page":"15002","DOI":"10.1038\/nrdp.2015.2","article-title":"Systemic sclerosis","volume":"1","author":"Allanore","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(24)00282-0","article-title":"CD19-targeting CAR T-cell therapy in patients with diffuse systemic sclerosis: a case series","volume":"7","author":"Auth","year":"2025","journal-title":"Lancet Rheumatol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"Lancet"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-225174","article-title":"Third-generation CD19.CAR-T cell-containing combination therapy in Scl70+ systemic sclerosis","volume":"83","author":"Merkt","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1114576","article-title":"Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis","volume":"370","author":"van Bon","year":"2014","journal-title":"N Engl J Med"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.6368","article-title":"Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial","volume":"311","author":"van Laar","year":"2014","journal-title":"JAMA"},{"key":"B123","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1056\/NEJMoa1703327","article-title":"Myeloablative autologous stem-cell transplantation for severe scleroderma","volume":"378","author":"Sullivan","year":"2018","journal-title":"N Engl J Med"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-019-0322-7","article-title":"Shared and distinct mechanisms of fibrosis","volume":"15","author":"Distler","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2015.10.005","article-title":"Systemic sclerosis: New evidence re-enforces the role of B cells","volume":"15","author":"Sakkas","year":"2016","journal-title":"Autoimmun Rev"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1002\/art.24249","article-title":"B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis","volume":"60","author":"Lafyatis","year":"2009","journal-title":"Arthritis Rheum"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep093","article-title":"Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study","volume":"49","author":"Daoussis","year":"2010","journal-title":"Rheumatol (Oxford)"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2016.10.003","article-title":"A multicenter, open-label, comparative study of B-cell depletion therapy with rituximab for systemic sclerosis-associated interstitial lung disease","volume":"46","author":"Daoussis","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30318-0","article-title":"Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Khanna","year":"2020","journal-title":"Lancet Respir Med"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(24)00377-1","article-title":"CAR T-cell therapy in autoimmune diseases: where are we and where are we going","volume":"7","author":"Scherlinger","year":"2025","journal-title":"Lancet Rheumatol"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2024.12.1066","article-title":"Chimeric antigen receptor-modified T-cell therapy: recent updates and challenges in autoimmune diseases","volume":"155","author":"Ca\u00ebl","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-225823","article-title":"Clinical efficacy and autoantibody seroconversion with CD19-CAR T cell therapy in a patient with rheumatoid arthritis and coexisting myasthenia gravis","volume":"83","author":"Haghikia","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(23)00375-7","article-title":"Anti-CD19 CAR T cells for refractory myasthenia gravis","volume":"22","author":"Haghikia","year":"2023","journal-title":"Lancet Neurol"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2024.03.002","article-title":"CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis","volume":"5","author":"Fischbach","year":"2024","journal-title":"Med"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-694356","article-title":"Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy","volume":"128","author":"Bhoj","year":"2016","journal-title":"Blood"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aeb6424","article-title":"BCMA\/CD19 CAR T cell therapy for refractory myasthenia gravis: proteomic signatures and single-cell transcriptomics of disease flares","volume":"12","author":"Huang","year":"2026","journal-title":"Sci Adv"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(23)00194-1","article-title":"Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b\/2a study","volume":"22","author":"Granit","year":"2023","journal-title":"Lancet Neurol"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2408786","article-title":"BCMA-targeted T-cell-engager therapy for autoimmune disease","volume":"391","author":"Hagen","year":"2024","journal-title":"N Engl J Med"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B140","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B141","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"B142","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"B144","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat Med"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat Med"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-16-0040","article-title":"Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"6","author":"Teachey","year":"2016","journal-title":"Cancer Discov"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023020578","article-title":"Immune effector cell-associated hematotoxicity: EHA\/EBMT consensus grading and best practice recommendations","volume":"142","author":"Rejeski","year":"2023","journal-title":"Blood"},{"key":"B151","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.bbmt.2019.08.003","article-title":"Late events after treatment with CD19-targeted chimeric antigen receptor modified T cells","volume":"26","author":"Cordeiro","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04390-6","article-title":"Decade-long leukaemia remissions with persistence of CD4+ CAR T cells","volume":"602","author":"Melenhorst","year":"2022","journal-title":"Nature"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.238634","article-title":"Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma","volume":"106","author":"Logue","year":"2021","journal-title":"Haematologica"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-07-793760","article-title":"Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy","volume":"131","author":"Hill","year":"2018","journal-title":"Blood"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019004000","article-title":"How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell Malignancies","volume":"136","author":"Hill","year":"2020","journal-title":"Blood"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2400209","article-title":"Secondary cancers after chimeric antigen receptor T-cell therapy","volume":"390","author":"Verdun","year":"2024","journal-title":"N Engl J Med"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2401361","article-title":"Risk of second tumors and T-cell lymphoma after CAR T-cell therapy","volume":"390","author":"Hamilton","year":"2024","journal-title":"N Engl J Med"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02862-6","article-title":"T cell lymphoma and secondary primary Malignancy risk after commercial CAR T cell therapy","volume":"30","author":"Ghilardi","year":"2024","journal-title":"Nat Med"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024166","article-title":"Second primary Malignancies after commercial CAR T-cell therapy: analysis of FDA Adverse Events Reporting System (FAERS)","volume":"143","author":"Elsallab","year":"2024","journal-title":"Blood"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02767-w","article-title":"Unanswered questions following reports of secondary Malignancies after CAR-T cell therapy","volume":"30","author":"Levine","year":"2024","journal-title":"Nat Med"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102476","article-title":"Innovative cellular therapies for autoimmune diseases: expert-based position statement and clinical practice recommendations from the EBMT","volume":"69","author":"Alexander","year":"2024","journal-title":"EClinicalMedicine"},{"key":"B163","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41409-019-0684-0","article-title":"Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE)","volume":"55","author":"Sharrack","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1081-3","article-title":"Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell Malignancies: a phase 1 dose escalation and expansion trial","volume":"26","author":"Shah","year":"2020","journal-title":"Nat Med"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30115-2","article-title":"A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial","volume":"6","author":"Yan","year":"2019","journal-title":"Lancet Haematol"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf6756","article-title":"Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease","volume":"353","author":"Ellebrecht","year":"2016","journal-title":"Science"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1172\/JCI138416","article-title":"Antigen-specific B cell depletion for precision therapy of mucosal pemphigus vulgaris","volume":"130","author":"Lee","year":"2020","journal-title":"J Clin Invest"},{"key":"B168","doi-asserted-by":"publisher","first-page":"3989","DOI":"10.1158\/1078-0432.CCR-13-2510","article-title":"Genetic modification of T cells redirected toward CS1 enhances eradication of myeloma cells","volume":"20","author":"Chu","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.04.024","article-title":"A rational strategy for reducing on-target off-tumor effects of CD38-chimeric antigen receptors by affinity optimization","volume":"25","author":"Drent","year":"2017","journal-title":"Mol Ther"},{"key":"B170","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.omtm.2016.12.006","article-title":"Global manufacturing of CAR T cell therapy","volume":"4","author":"Levine","year":"2017","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0051-2","article-title":"'Off-the-shelf' allogeneic CAR T cells: development and challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaj2013","article-title":"Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells","volume":"9","author":"Qasim","year":"2017","journal-title":"Sci Transl Med"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32334-5","article-title":"Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies","volume":"396","author":"Benjamin","year":"2020","journal-title":"Lancet"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02182-7","article-title":"Allogeneic BCMA-targeting CAR T cells in relapsed\/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results","volume":"29","author":"Mailankody","year":"2023","journal-title":"Nat Med"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1126\/science.aba7365","article-title":"CRISPR-engineered T cells in patients with refractory cancer","volume":"367","author":"Stadtmauer","year":"2020","journal-title":"Science"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0326-5","article-title":"Reprogramming human T cell function and specificity with non-viral genome targeting","volume":"559","author":"Roth","year":"2018","journal-title":"Nature"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2678","article-title":"Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy","volume":"31","author":"Themeli","year":"2013","journal-title":"Nat Biotechnol"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N Engl J Med"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2024.06.027","article-title":"Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis","volume":"187","author":"Wang","year":"2024","journal-title":"Cell"},{"key":"B180","doi-asserted-by":"publisher","first-page":"315ra189","DOI":"10.1126\/scitranslmed.aad4134","article-title":"Type 1 diabetes immunotherapy using polyclonal regulatory T cells","volume":"7","author":"Bluestone","year":"2015","journal-title":"Sci Transl Med"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.01.049","article-title":"Amelioration of colitis by genetically engineered murine regulatory T cells redirected by antigen-specific chimeric receptor","volume":"136","author":"Elinav","year":"2009","journal-title":"Gastroenterology"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1172\/JCI82771","article-title":"Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor","volume":"126","author":"MacDonald","year":"2016","journal-title":"J Clin Invest"},{"key":"B183","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.stem.2026.02.006","article-title":"In vivo CAR-Tfh cell reprogramming restores tolerance in a mouse model of autoimmune hepatitis","volume":"33","author":"Zheng","year":"2026","journal-title":"Cell Stem Cell"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.126194","article-title":"Chimeric antigen receptor costimulation domains modulate human regulatory T cell function","volume":"5","author":"Boroughs","year":"2019","journal-title":"JCI Insight"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2219086120","article-title":"Tonic-signaling chimeric antigen receptors drive human regulatory T cell exhaustion","volume":"120","author":"Lamarche","year":"2023","journal-title":"Proc Natl Acad Sci USA"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.686439","article-title":"Precision engineering of an anti-HLA-A2 chimeric antigen receptor in regulatory T cells for transplant immune tolerance","volume":"12","author":"Muller","year":"2021","journal-title":"Front Immunol"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0232-6","article-title":"Treg cell-based therapies: challenges and perspectives","volume":"20","author":"Raffin","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2025.101480","article-title":"HLA-A2 CAR\/IL-2-CISC engineered Treg display robust in vitro and in vivo antigen-specific regulatory function","volume":"33","author":"Honaker","year":"2025","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1106152","article-title":"Inducible apoptosis as a safety switch for adoptive cell therapy","volume":"365","author":"Di Stasi","year":"2011","journal-title":"N Engl J Med"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-01-545020","article-title":"A highly compact epitope-based marker\/suicide gene for easier and safer T-cell therapy","volume":"124","author":"Philip","year":"2014","journal-title":"Blood"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.1126\/science.aab4077","article-title":"Remote control of therapeutic T cells through a small molecule-gated chimeric receptor","volume":"350","author":"Wu","year":"2015","journal-title":"Science"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.01.011","article-title":"Precision tumor recognition by T cells with combinatorial antigen-sensing circuits","volume":"164","author":"Roybal","year":"2016","journal-title":"Cell"},{"key":"B193","doi-asserted-by":"publisher","first-page":"215ra172","DOI":"10.1126\/scitranslmed.3006597","article-title":"PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses","volume":"5","author":"Fedorov","year":"2013","journal-title":"Sci Transl Med"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.09.011","article-title":"Engineering T cells with customized therapeutic response programs using synthetic notch receptors","volume":"167","author":"Roybal","year":"2016","journal-title":"Cell"},{"key":"B195","doi-asserted-by":"publisher","first-page":"6080","DOI":"10.1038\/s41467-020-19486-2","article-title":"In vitro-transcribed antigen receptor mRNA nanocarriers for transient expression in circulating T cells in vivo","volume":"11","author":"Parayath","year":"2020","journal-title":"Nat Commun"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.1021\/acs.nanolett.9b04246","article-title":"Ionizable lipid nanoparticle-mediated mRNA delivery for human CAR T cell engineering","volume":"20","author":"Billingsley","year":"2020","journal-title":"Nano Lett"},{"key":"B197","doi-asserted-by":"publisher","DOI":"10.1002\/EXP.20240109","article-title":"Extracellular vesicle-based mRNA therapeutics and vaccines","volume":"5","author":"Li","year":"2025","journal-title":"Explor (Beijing)"},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.1126\/science.abm0594","article-title":"CAR T cells produced in vivo to treat cardiac injury","volume":"375","author":"Rurik","year":"2022","journal-title":"Science"},{"key":"B199","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s40164-025-00725-5","article-title":"In vivo CAR-T cell engineering: concept, research progress, potential challenges and enhancement strategies","volume":"14","author":"Chen","year":"2025","journal-title":"Exp Hematol Oncol"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.1038\/s42255-022-00537-5","article-title":"CAR-based therapies: opportunities for immuno-medicine beyond cancer","volume":"4","author":"Aghajanian","year":"2022","journal-title":"Nat Metab"},{"key":"B201","doi-asserted-by":"publisher","DOI":"10.1126\/science.abf1970","article-title":"Single-cell RNA-seq reveals cell type-specific molecular and genetic associations to lupus","volume":"376","author":"Perez","year":"2022","journal-title":"Science"},{"key":"B202","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02079","article-title":"Cost effectiveness of chimeric antigen receptor T-cell therapy in multiply relapsed or refractory adult large B-cell lymphoma","volume":"37","author":"Lin","year":"2019","journal-title":"J Clin Oncol"},{"key":"B203","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-020-0956-8","article-title":"Value and affordability of CAR T-cell therapy in the United States","volume":"55","author":"Fiorenza","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of anifrolumab in active systemic lupus erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N Engl J Med"},{"key":"B205","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00578-X","article-title":"Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"397","author":"Rovin","year":"2021","journal-title":"Lancet"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1913968\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T10:25:54Z","timestamp":1786962354000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1913968\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,17]]},"references-count":205,"alternative-id":["10.3389\/fimmu.2026.1913968"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1913968","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,17]]},"article-number":"1913968"}}